Bumetanide Patent Expiration
Bumetanide was first introduced by Validus Pharmaceuticals Llc
Bumetanide Patents
Given below is the list of patents protecting Bumetanide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Enbumyst | US12558330 | Methods And Compositions For Treating Edema Refractory To Oral Diuretics | May 14, 2045 | Corstasis Therap |
| Enbumyst | US11123319 | Methods And Compositions For Treating Edema Refractory To Oral Diuretics | Dec 04, 2040 | Corstasis Therap |
| Enbumyst | US11260038 | Dec 04, 2040 | Corstasis Therap | |
| Enbumyst | US12329731 | Methods And Compositions For Treating Edema Refractory To Oral Diuretics | Dec 04, 2040 | Corstasis Therap |
Bumetanide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Bumetanide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Bumetanide vs. Furosemide in Cirrhosis | Stacy Johnson | NA |
RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Mechanisms of Diuretic Resistance in Heart Failure, Aim 1 | Yale University | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |
| Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | Memorial Sloan Kettering Cancer Center | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE1, PHASE2 |
| Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models | Fei Li | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |